Shots:

• The P-III trial (monarchE) evaluates Verzenio (150mg, BID) + ET vs ET alone in a ratio (1:1) in 5637 patients with HR+, HER2-, node-positive, high-risk EBC
• At the data cut-off of July 2022 in the ITT population, reduction in risk of developing invasive & metastatic disease (33.6% & 34.1%), 4yr. IDFS rate (85.8% & 88.4% vs 79.4% & 82.5%) with an absolute difference of 6.4% & 5.9% vs 2.8% & 2.5% @2yr. The results were published in The Lancet Oncology & incl. investigational use in the ITT & cohort 1 populations
• The results were consistent with prior analyses, benefits were also observed across all prespecified subgroups regardless of Ki-67 score & fewer deaths were observed (5.6% vs 6.1%) OS data remain immature with no new safety findings

Ref: PRNewswire | Image: Eli Lilly